E-viri
Recenzirano
Odprti dostop
-
Garcia, Gustavo; Sharma, Arun; Ramaiah, Arunachalam; Sen, Chandani; Purkayastha, Arunima; Kohn, Donald B.; Parcells, Mark S.; Beck, Sebastian; Kim, Heeyoung; Bakowski, Malina A.; Kirkpatrick, Melanie G.; Riva, Laura; Wolff, Karen C.; Han, Brandon; Yuen, Constance; Ulmert, David; Purbey, Prabhat K.; Scumpia, Philip; Beutler, Nathan; Rogers, Thomas F.; Chatterjee, Arnab K.; Gabriel, Gülsah; Bartenschlager, Ralf; Gomperts, Brigitte; Svendsen, Clive N.; Betz, Ulrich A.K.; Damoiseaux, Robert D.; Arumugaswami, Vaithilingaraja
Cell reports, 04/2021, Letnik: 35, Številka: 1Journal Article
SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells. These drug inhibitors are in various stages of clinical trials. We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are critical for SARS-CoV-2 infection. A drug-protein interaction-based secondary screen confirmed compounds, such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity. Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step. Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well. Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions. Display omitted •Kinase inhibitor screen identified 34 compounds with anti-SARS-CoV-2 activity•Inhibitors targeted mTOR-PI3K-AKT and DNA-damage response (DDR) signaling pathways•ATR kinase inhibitor berzosertib blocked SARS-CoV-1, SARS-CoV-2, and MERS-CoV infection•Treatment with berzosertib blocks SARS-CoV-2 at post-entry level in epithelial cells Garcia et al. screen a library of drug compounds and identify SARS-CoV-2-specific antiviral agents. These drugs have been shown to modulate cellular signaling cascades, including mTOR-PI3K-AKT and DNA-damage response (DDR) pathways. A highly effective drug candidate, berzosertib, blocked multiple coronaviruses, such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV, thus providing a potential therapeutic against COVID-19.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.